NASDAQ:CDT

CDT Equity Q1 2025 Earnings Results & Report

CDT Equity logo
$0.34 -0.03 (-8.49%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CDT Equity reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$19,800,000.00.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

CDT Equity EPS Results

Actual EPS
-$19,800,000.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CDT Equity Q1 2025 Earnings FAQ

CDT Equity (NASDAQ:CDT) reported earnings of -$19,800,000.00 per share for Q1 2025. The report was announced on Thursday, May 15, 2025.

CDT Equity Earnings Headlines

The $40 trillion number nobody won on Tuesday will touch
Democrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion a year in interest on it didn't change. Central banks bought 863 tonnes of gold in 2025 and another 289 tonnes in the second quarter of this year. Gold broke $5,000 and had its best year since 1979 in 2025. Wall Street's biggest bank forecasts gold above $6,000 by early 2027.tc pixel
CDT Equity Announces 1-for-20 Reverse Stock Split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

CDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs.

Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch.

Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.

View CDT Equity Profile